Vendor source
Reviewed 11 May 2026
Completeness Strong (64%)
TRACE4OC
DeepTrace Technologies SrlTRACE4OC provides the woman's level of risk (very low risk or medium-high risk) of being affected with ovarian cancer at the date of the TRACE4OC-processed USI investigation of an adnexal mass, combined with the serum level test for Cancer Antigen 125 (CA-125), performed no earlier than and no later than one month from the USI study, and with the current woman's menopausal state (premenopausal or post menopause).
Supported by 1 paper
General Information
Product name
Company
Modality
Main task
Not specified
Subspeciality
Disease targeted
Regulatory Information
Pathway:
MDD
Class:
Class I
Verified by Health AI Register
Other certifications
Not specified
Technical Specifications
Patient population age
Not specified
Input
Input format
Output
Output format
Integration
Deployment
Trigger for analysis
Processing time
Population
Market Presence
On market since
AI Platforms
Resellers
Not specified
Countries present
Not specified
Paying clinical customers
Not specified
Research/test users
Not specified
Pricing Information
Pricing model
Based on
Source: Vendor | First published: Nov 18, 2021 | Last updated: May 11, 2026